Evidence map›Paper›PMID 34768771›Full record

ArticleInternational journal of molecular sciences2021

Tackling the Biological Meaning of the Human Olfactory Bulb Dyshomeostatic Proteome across Neurological Disorders: An Integrative Bioinformatic Approach.

Paz Cartas-Cejudo, Mercedes Lachén-Montes, Joaquín Fernández-Irigoyen, Enrique Santamaría

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Paz Cartas-CejudoClinical Neuroproteomics Unit, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Navarra Institute for Health Research, Universidad Pública de Navarra (UPNA), IdiSNA, 3, 31008 Pamplona, Spain.ORCID 0000-0002-6182-7445
Mercedes Lachén-MontesClinical Neuroproteomics Unit, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Navarra Institute for Health Research, Universidad Pública de Navarra (UPNA), IdiSNA, 3, 31008 Pamplona, Spain.
Joaquín Fernández-IrigoyenClinical Neuroproteomics Unit, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Navarra Institute for Health Research, Universidad Pública de Navarra (UPNA), IdiSNA, 3, 31008 Pamplona, Spain.ORCID 0000-0001-5072-4099
Enrique SantamaríaClinical Neuroproteomics Unit, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Navarra Institute for Health Research, Universidad Pública de Navarra (UPNA), IdiSNA, 3, 31008 Pamplona, Spain.ORCID 0000-0001-8046-8102
Universidad Publica de Navarra · ES

Funding

Department of Economic and Business Development from Government of 260 Navarra 0011-1411-2020-000028Spanish Ministry of Science Innovation and Universities PID2019-110356RB- 259 I00/ AEI / 10.13039/501100011033
6 · The paper itself

Abstract

Olfactory dysfunction is considered an early prodromal marker of many neurodegenerative diseases. Neuropathological changes and aberrant protein aggregates occur in the olfactory bulb (OB), triggering a tangled cascade of molecular events that is not completely understood across neurological disorders. This study aims to analyze commonalities and differences in the olfactory protein homeostasis across neurological backgrounds with different spectrums of smell dysfunction. For that, an integrative analysis was performed using OB proteomics datasets derived from subjects with Alzheimer's disease (AD), Parkinson's disease (PD), mixed dementia (mixD), dementia with Lewy bodies (DLB), frontotemporal lobar degeneration (FTLD-TDP43), progressive supranuclear palsy (PSP) and amyotrophic lateral sclerosis (ALS) with respect to OB proteome data from neurologically intact controls. A total of 80% of the differential expressed protein products were potentially disease-specific whereas the remaining 20% were commonly altered across two, three or four neurological phenotypes. A multi-level bioinformatic characterization revealed a subset of potential disease-specific transcription factors responsible for the downstream effects detected at the proteome level as well as specific densely connected protein complexes targeted by several neurological phenotypes. Interestingly, common or unique pathways and biofunctions were also identified, providing novel mechanistic clues about each neurological disease at olfactory level. The analysis of olfactory epithelium, olfactory tract and primary olfactory cortical proteotypes in a multi-disease format will functionally complement the OB dyshomeostasis, increasing our knowledge about the neurodegenerative process across the olfactory axis.

Indexed as

Alzheimer DiseaseAmyotrophic Lateral SclerosisComputational BiologyDatabases, FactualDementiaGene Expression RegulationHumansNervous System DiseasesNeurodegenerative DiseasesOlfactory BulbParkinson DiseaseProteomeProteostasisSupranuclear Palsy, ProgressiveSynucleinopathiesTranscription FactorsProteomeTranscription Factorsneurodegenerationolfactory bulbpathwaysproteomics

Identifiers

PMID34768771
PMCPMC8583219
OpenAlexW3205829420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.